Similar articles for PMID: 22586334

Year	Number of Results
1987	1
1989	1
1994	2
1997	2
2000	2
2001	3
2002	1
2003	6
2004	6
2005	2
2006	2
2007	2
2008	1
2009	5
2010	7
2011	9
2012	5
2013	4
2014	5
2015	7
2016	4
2017	7
2018	10
2019	12
2020	6
2021	6
2022	9
2023	1

1

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.

Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B. Corey-Bloom J, et al. CMAJ. 2012 Jul 10;184(10):1143-50. doi: 10.1503/cmaj.110837. Epub 2012 May 14. CMAJ. 2012. PMID: 22586334 Free PMC article. Clinical Trial.

2

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.

Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M. Vaney C, et al. Mult Scler. 2004 Aug;10(4):417-24. doi: 10.1191/1352458504ms1048oa. Mult Scler. 2004. PMID: 15327040 Clinical Trial.

3

[Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy].

Amato L, Minozzi S, Mitrova Z, Parmelli E, Saulle R, Cruciani F, Vecchi S, Davoli M. Amato L, et al. Epidemiol Prev. 2017 Sep-Dec;41(5-6):279-293. doi: 10.19191/EP17.5-6.AD01.069. Epidemiol Prev. 2017. PMID: 29119763 Free article. Review. Italian.

4

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group. Zajicek J, et al. Lancet. 2003 Nov 8;362(9395):1517-26. doi: 10.1016/S0140-6736(03)14738-1. Lancet. 2003. PMID: 14615106 Clinical Trial.

5

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.

Wade DT, Robson P, House H, Makela P, Aram J. Wade DT, et al. Clin Rehabil. 2003 Feb;17(1):21-9. doi: 10.1191/0269215503cr581oa. Clin Rehabil. 2003. PMID: 12617376 Clinical Trial.

6

Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial.

Cutter NC, Scott DD, Johnson JC, Whiteneck G. Cutter NC, et al. Arch Phys Med Rehabil. 2000 Feb;81(2):164-9. doi: 10.1016/s0003-9993(00)90135-7. Arch Phys Med Rehabil. 2000. PMID: 10668769 Clinical Trial.

7

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.

Wade DT, Makela P, Robson P, House H, Bateman C. Wade DT, et al. Mult Scler. 2004 Aug;10(4):434-41. doi: 10.1191/1352458504ms1082oa. Mult Scler. 2004. PMID: 15327042 Clinical Trial.

8

Patterns of cannabis use among patients with multiple sclerosis.

Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Clark AJ, et al. Neurology. 2004 Jun 8;62(11):2098-100. doi: 10.1212/01.wnl.0000127707.07621.72. Neurology. 2004. PMID: 15184623

9

Do cannabinoids reduce multiple sclerosis-related spasticity?

Thaera GM, Wellik KE, Carter JL, Demaerschalk BM, Wingerchuk DM. Thaera GM, et al. Neurologist. 2009 Nov;15(6):369-71. doi: 10.1097/NRL.0b013e3181bf5572. Neurologist. 2009. PMID: 19901724

10

Cannabis use in people with multiple sclerosis and spasticity: A cross-sectional analysis.

Rice J, Hugos C, Hildebrand A, Cameron M. Rice J, et al. Mult Scler Relat Disord. 2020 Jun;41:102009. doi: 10.1016/j.msard.2020.102009. Epub 2020 Feb 11. Mult Scler Relat Disord. 2020. PMID: 32086163

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed